30413-84-4

Usage

Uses

Used in Pain Management:
Corydalmine is used as an analgesic agent for its ability to alleviate pain. It is particularly effective in managing chronic pain conditions, making it a valuable component in pain management therapies.
Used in Inflammation Reduction:
Corydalmine is used as an anti-inflammatory agent for its capacity to reduce inflammation. This application is beneficial in treating various inflammatory conditions, contributing to the overall well-being of patients.
Used in Cancer Therapy Research:
Corydalmine is being investigated as a potential anti-cancer agent. Its use in this field is based on the compound's ability to exhibit anti-tumor activity, which could potentially lead to new cancer treatment options.
Used in Liver Protection:
Corydalmine is used as a hepatoprotective agent for its potential to protect the liver from damage. This application is significant in the context of liver diseases and conditions that require liver protection.
Used in Menstrual Discomfort Relief:
Corydalmine is used as a remedy for menstrual discomfort. Its application in this area is based on the compound's ability to alleviate pain and discomfort associated with menstruation, providing relief to women experiencing these symptoms.
Used in Traditional Chinese Medicine:
Corydalmine is used as a therapeutic agent in traditional Chinese medicine for its various health benefits. Its use in this context is rooted in the historical and cultural practices of utilizing plant-based remedies for treating a range of health conditions.
Used in Native American Medicine:
Corydalmine is used as a medicinal agent in Native American medicine for its therapeutic properties. Similar to its use in traditional Chinese medicine, corydalmine is valued for its ability to address various health issues within the framework of Native American healing practices.

InChI:InChI=1/C20H23NO4/c1-23-18-9-13-6-7-21-11-15-12(4-5-17(22)20(15)25-3)8-16(21)14(13)10-19(18)24-2/h4-5,9-10,16,22H,6-8,11H2,1-3H3/t16-/m0/s1

Upstream product

• 1429118-64-8 C₂₉H₃₃NO₆ 
• 1429118-48-8 3-(benzyloxy)-6-(2-((3,4-dimethoxyphenethyl)amino)-2-oxoethyl)-2-methoxybenzyl acetate 
• 1429118-40-0 2-(4-(benzyloxy)-2-(hydroxymethyl)-3-methoxyphenyl)-N-(3,4-dimethoxyphenethyl)acetamide 
• 65615-22-7 7-(benzyloxy)-8-hydroxy-1H-isochromen-3(4H)-one 
• 28988-68-3 2-(4-(benzyloxy)-3-hydroxyphenyl)acetic acid 
• 101111-25-5 methyl 2-(4-(benzyloxy)-3-bromophenyl)acetate 
• 65615-23-8 7-(benzyloxy)-8-methoxy-1H-isochromen-3(4H)-one 
• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 
• 5884-48-0 2-(4-(benzyloxy)-3-bromophenyl)acetic acid 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 1422431-58-0 (S)-10-(benzyloxy)-2,3,9-trimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline 
• 1429118-81-9 (S)-(3-(benzyloxy)-6-((6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-2-methoxyphenyl)methanol 

Relevant academic research and scientific papers

Preparation method of isoquinoline alkaloid L-corydalmine

The invention belongs to the field of medical chemistry, and provides a preparation method of L-corydalmine or pharmaceutically acceptable salts thereof. The method comprises the following steps of: in the presence of an organic solvent, catalyzing by pal

Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors

Cocaine addiction remains a serious challenge for clinical and medical research because there is no effective pharmacological treatment. L-THP, a natural product isolated from Corydalis yanhusuo W.T. Wang, is one of the most frequently used traditional herbs to treat drug addiction in China. Our laboratory first reported that its demethylated metabolites L-ICP, L-CD, and L-CP had high affinity at dopamine D1, D2, and D5 receptors. Here we report the chemical synthesis of these metabolites and other derivatives and their binding affinities at dopamine receptors. The synthesis of these bioactive metabolites will allow further in vivo study of their potential in treating cocaine addiction.

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D1, D2 and serotonin 5-HT1A multi-action profile

An effective and rapid method for the microwave-assisted preparation of the key intermediate for the total synthesis of tetrahydroprotoberberines (THPBs) including l-stepholidine (l-SPD) was developed. Thirty-one THPB derivatives with diverse substituents on A and D ring were synthesized, and their binding affinity to dopamine D1, D2 and serotonin 5-HT 1A and 5-HT2A receptors were determined. Compounds 18k and 18m were identified as partial agonists at the D1 receptor with Ki values of 50 and 6.3 nM, while both compounds act as D2 receptor antagonists (Ki = 305 and 145 nM, respectively) and 5-HT1A receptor full agonists (Ki = 149 and 908 nM, respectively). These two THPBs compounds exerted antipsychotic actions in animal models. Further electrophysiological studies employing single-unit recording in intact animals demonstrated that 18k-excited dopaminergic (DA) neurons are associated with its 5-HT1A receptor agonistic activity. These results suggest that these two compounds targeted to multiple neurotransmitter receptors may present novel lead drugs with new pharmacological profiles for the treatment of schizophrenia.